24/7 Market News Snapshot 27 August, 2025 – Mannkind Corporation (NASDAQ:MNKD)
DENVER, Colo., 27 August, 2025 (www.247marketnews.com) – (NASDAQ:MNKD) are discussed in this article.
MannKind Corporation is experiencing a noteworthy surge in market activity, opening at $4.20 and currently trading at $4.545, an increase of approximately 11.67%. This upward movement follows a previous close at $4.070, supported by an impressive trading volume of 6.75 million shares, indicating heightened investor interest and potential for a breakout. Technical indicators reveal that MannKind is nearing critical resistance levels, warranting close monitoring by traders, as these levels may present opportunities for profit-taking or further strategic positioning. Overall, the current trend reflects a bullish sentiment in the market toward MannKind.
In addition to market activity, MannKind is excited to announce the expansion of its collaboration with United Therapeutics Corporation. United Therapeutics recently opted to develop a second dry powder inhalation therapy under the pre-existing agreement, building on the successful launch of Tyvaso DPI, which received FDA approval in May 2022. The new agreement allows MannKind to utilize its proprietary Technosphere® platform to formulate an investigational molecule, while United Therapeutics will lead the preclinical and clinical development of this promising therapy aimed at treating pulmonary hypertension.
Michael Castagna, PharmD, CEO of MannKind Corporation, expressed enthusiasm about the deepening partnership, emphasizing the company’s commitment to bringing innovative inhaled therapies to patients with pulmonary hypertension. This collaboration underscores both the strength of the partnership and the adaptability of MannKind’s dry powder formulations and inhalation devices.
MannKind will receive an upfront payment of $5 million as part of the expanded agreement, along with opportunities for additional development milestone payments totaling up to $35 million and 10% royalties on net sales of any resulting product. The formulation and development activities for the new investigational molecule are slated to commence immediately, reinforcing MannKind’s dedication to addressing significant unmet medical needs in pulmonary diseases and endocrine conditions.
Related news for (MNKD)
- Cybersecurity Surges, Biotech Booms & SaaS Shifts- 7 Hot Stocks Lighting Up into the Close
- MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
- MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
- MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association’s 85th Scientific Sessions in Chicago, June 20-23